Fischer Medical Ventures Limited announced its unaudited financial results for Q3FY26 ended December 31, 2025, demonstrating strong consolidated performance alongside key corporate developments. The Board of Directors approved these results in their meeting held on January 30, 2026, along with several significant organizational changes.

Financial Performance Overview

The company's consolidated operations showed robust growth with total revenue reaching ₹10,218.33 lakhs for Q3FY26, compared to ₹1,212.66 lakhs in the corresponding quarter of the previous year. This substantial increase was primarily driven by revenue from operations of ₹10,109.52 lakhs, marking a significant improvement from ₹1,174.85 lakhs in Q3FY24. The company achieved an EBITDA of 216M rupees in Q3 compared to 5M rupees in the previous year, with EBITDA margin improving significantly to 21.34% from 4.26%.

For the nine-month period ended December 31, 2025, consolidated revenue from operations reached ₹21,084.52 lakhs compared to ₹6,152.45 lakhs in the corresponding period of FY24, while net profit stood at ₹3,813.89 lakhs against a loss of ₹10.42 lakhs in the previous year.

Standalone Performance Analysis

The standalone operations presented a mixed picture for Q3FY26. Revenue from operations was ₹131.50 lakhs, while the company reported a net loss of ₹166.93 lakhs for the quarter. However, the nine-month standalone performance showed revenue from operations of ₹1,328.42 lakhs with a net loss of ₹144.11 lakhs.

Key Corporate Developments

The company announced several important organizational changes during the Board meeting. Mr. Aravindkumar V, Company Secretary & Compliance Officer and Key Managerial Personnel, tendered his resignation effective from the closure of business hours on February 10, 2026, citing personal reasons and career opportunities outside the organization.

Subsidiary Restructuring Initiative

The Board approved a significant restructuring proposal for Fischer Hospitality Sdn. Bhd. (FHSB), the company's Malaysian subsidiary. Under the new structure, a Malaysian trustee will hold 51% of FHSB shares on behalf of Fischer Medical Ventures, while the company will directly hold the remaining 49%. This restructuring has been reviewed and approved by the Audit Committee.

Regulatory Compliance and Share Capital

The company addressed a regulatory matter concerning delayed submission of Related Party Transactions for the half-year ended September 30, 2025. The Board acknowledged this non-compliance was not willful and committed to ensuring timely future submissions. The paid-up equity share capital stood at ₹6,485.15 lakhs with a face value of Re. 1/- per share, following the share subdivision approved in July 2025.

Auditor Review and Compliance

Bilimoria Mehta & Co., Chartered Accountants, conducted limited reviews of both standalone and consolidated financial results. The auditors confirmed that the financial statements comply with Indian Accounting Standards (Ind AS) and SEBI listing regulations. The consolidated results include subsidiaries and associates across multiple jurisdictions, with appropriate conversion adjustments made for international operations.

Fischer Medical Ventures Limited has announced an internal group reorganisation involving the transfer of shares in its foreign subsidiary to enhance operational efficiency. The company informed stock exchanges on January 21, 2026, about the Executive Business Committee's approval of this strategic move.

Executive Committee Approves Share Transfer

The Executive Business Committee of Fischer Medical Ventures, operating under its delegated authority, has approved the transfer of shares held by the company in PellucidCare Health Innovations Pte Ltd to FlynnCare Health Innovations Private Limited. PellucidCare Health Innovations Pte Ltd, based in Singapore, was formerly known as FMV Healthcare Pte Ltd.

Strategic Rationale and Impact

The company stated that this transfer is being undertaken specifically for administrative and operational efficiency purposes. Fischer Medical Ventures emphasised that the reorganisation represents an internal restructuring between the holding company and its wholly owned subsidiary.

The management highlighted several key aspects of the transaction:

• No change in ultimate ownership of the foreign subsidiary
• No alteration in control or management structure
• No impact on economic interest in the subsidiary
• No material effect on consolidated financials

Regulatory Compliance and Disclosure

Fischer Medical Ventures made this disclosure in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company specifically referenced Schedule III of these regulations in its communication to both BSE Limited and National Stock Exchange of India Limited.

Corporate Structure Implications

The transaction maintains the existing corporate structure hierarchy while optimising internal operations. Since FlynnCare Health Innovations Private Limited is a wholly owned subsidiary of Fischer Medical Ventures Limited, the reorganisation keeps all entities within the same corporate family.

The company secretary and compliance officer, Aravindkumar V, signed the disclosure document digitally on January 21, 2026, ensuring proper documentation and regulatory compliance for this internal restructuring initiative.